Biospecimen Collection for Breast Cancer

Recruiting at 9 trial locations

Overseen By Jie Willey

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: M.D. Anderson Cancer Center

Disqualifiers: None

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1200 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to collect and study blood, tissue, and stool samples from patients with inflammatory or invasive breast cancer. Researchers hope to find better ways to treat and understand this type of breast cancer in the future. Participants will complete questionnaires, participate in interviews, and allow researchers to review their medical data. This trial may suit individuals diagnosed with inflammatory or invasive breast cancer or those highly suspected of having it. As an unphased trial, joining offers a unique opportunity to contribute to groundbreaking research that could lead to new treatment options.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to create a comprehensive research tissue registry for patients with inflammatory or invasive breast cancer. Unlike standard treatments that focus on shrinking tumors or slowing cancer spread, this project collects biospecimens and medical data to better understand the disease at a molecular level. By gathering blood, tissue, and stool samples, along with detailed patient interviews and questionnaires, the trial could unveil new insights into the biology of these aggressive breast cancers. This could eventually lead to more targeted and effective treatments in the future.

Who Is on the Research Team?

VIcente Valero, MD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only).

Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis.

Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) [Cohort I] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Participants complete questionnaires and participate in interviews over 30 minutes. Collection of medical data and blood, tissue, and stool samples.

Up to 2 years

Follow-up

Participants are monitored for changes in microbiome and correlation to toxicity during the course of treatment

Up to 2 years

What Are the Treatments Tested in This Trial?

Interventions

• Biospecimen Collection
• Interview
• Medical Chart Review
• Questionnaire Administration

How Is the Trial Designed?

Group I: Observational (biospecimen and medical data collection) Experimental Treatment 4 Interventions

Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Texas Appropriation for Rare and Aggressive diseases

Collaborator

Trials

1

Recruited

1,200+